Drug-associated dysfunction of mitochondria (mt) is believed to play a role in the aetiology of the various adverse symptoms that occur in HIV-infected patients treated with the nucleoside reverse transcriptase inhibitors (NRTIs). Switching to drugs with less mt toxicity may be of benefit in HIV-infected patients receiving antiretroviral therapy containing stavudine (d4T), but the efficacy and the safety of this strategy in paediatric population is unknown. We have analysed the effect of the switch from d4T to tenofovir (TDF), paying particular attention to the maintenance of the immunovirological status and lipid profile.
Effects on mitochondria and thymus of the switch from stavudine to tenofovir in HIV-infected children / Rosso, R; Nasi, Milena; Pinti, Marcello; Nemes, Elisa; Roat, Erika; Di Biagio, A; Repetto, E; Bassetti, M; Cossarizza, Andrea; Bassetti, D.. - In: ANTIVIRAL THERAPY. - ISSN 1359-6535. - STAMPA. - 10:8(2005), pp. L 48-L 48. (Intervento presentato al convegno 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV tenutosi a Dublin, Ireland nel 13–16 November 2005).
Effects on mitochondria and thymus of the switch from stavudine to tenofovir in HIV-infected children
NASI, Milena;PINTI, Marcello;NEMES, Elisa;ROAT, ERIKA;COSSARIZZA, Andrea;
2005
Abstract
Drug-associated dysfunction of mitochondria (mt) is believed to play a role in the aetiology of the various adverse symptoms that occur in HIV-infected patients treated with the nucleoside reverse transcriptase inhibitors (NRTIs). Switching to drugs with less mt toxicity may be of benefit in HIV-infected patients receiving antiretroviral therapy containing stavudine (d4T), but the efficacy and the safety of this strategy in paediatric population is unknown. We have analysed the effect of the switch from d4T to tenofovir (TDF), paying particular attention to the maintenance of the immunovirological status and lipid profile.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
